Halozyme Therapeutics Inc (HALO)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 80.80% | 78.34% | 75.89% | 76.44% | 76.80% | 76.66% | 77.42% | 77.51% | 78.90% | 79.54% | 81.53% | 83.22% | 81.64% | 81.40% | 82.28% | 83.16% | 83.79% | 83.07% | 71.99% | 71.60% |
| Operating profit margin | 54.32% | 50.35% | 46.04% | 43.95% | 40.71% | 39.84% | 39.56% | 34.85% | 40.53% | 42.98% | 49.61% | 63.80% | 62.24% | 64.14% | 63.44% | 59.84% | 53.91% | 17.32% | -16.77% | -44.89% |
| Pretax margin | 54.87% | 50.68% | 47.72% | 45.44% | 42.01% | 40.73% | 37.47% | 32.16% | 37.71% | 40.12% | 47.87% | 62.52% | 56.06% | 57.66% | 55.55% | 49.35% | 48.32% | 10.82% | -21.99% | -48.76% |
| Net profit margin | 43.74% | 41.43% | 38.62% | 36.94% | 33.96% | 32.52% | 30.21% | 25.76% | 30.62% | 36.37% | 75.11% | 92.23% | 90.84% | 88.36% | 55.45% | 49.23% | 48.24% | 10.79% | -22.00% | -48.75% |
The profitability ratios of Halozyme Therapeutics Inc have shown varied trends over the years.
1. Gross Profit Margin: The gross profit margin has generally been high, ranging from around 71% to 83%. However, there has been a slight decline in recent periods, falling below 80% in the most recent quarters of 2024.
2. Operating Profit Margin: The operating profit margin has displayed significant fluctuations, starting from negative values in early 2020 and gradually improving to reach levels above 50% by the end of 2024. The margin experienced some volatility along the way but generally showed an increasing trend.
3. Pretax Margin: The pretax margin also exhibited fluctuations but generally trended upwards from negative values to reach around 55% to 60% by the end of 2024. This indicates improving profitability before taxes over the years.
4. Net Profit Margin: The net profit margin, reflecting the company's bottom-line profitability, started from negative values in 2020 and improved consistently over time. It reached levels above 40% by the end of 2024, showcasing a strong performance in generating profits relative to its revenue.
Overall, while there were fluctuations in profitability ratios, particularly at the operating level, Halozyme Therapeutics Inc has shown a positive trend in improving its profitability margins over the years, with a notable increase in net profit margin indicating efficient cost management and revenue generation.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 26.73% | 22.52% | 20.42% | 20.60% | 19.48% | 16.43% | 16.91% | 14.46% | 14.53% | 13.38% | 13.58% | 25.88% | 24.98% | 25.05% | 25.51% | 20.51% | 24.87% | 6.60% | -5.74% | -14.99% |
| Return on assets (ROA) | 21.52% | 18.53% | 17.13% | 17.31% | 16.25% | 13.42% | 12.91% | 10.69% | 10.98% | 11.33% | 20.55% | 37.42% | 36.46% | 34.51% | 22.30% | 16.87% | 22.26% | 4.11% | -7.53% | -16.28% |
| Return on total capital | 155.35% | 107.98% | 146.99% | 228.25% | 438.01% | 134.86% | 205.92% | 374.30% | 156.28% | 254.53% | 82.38% | 115.91% | 140.50% | 105.85% | 220.08% | 297.55% | 99.08% | 41.05% | -22.30% | -114.45% |
| Return on equity (ROE) | 122.06% | 86.69% | 116.54% | 179.30% | 336.00% | 101.90% | 154.74% | 275.83% | 119.04% | 217.75% | 124.89% | 167.11% | 204.47% | 145.24% | 191.00% | 241.26% | 85.46% | 21.74% | -37.60% | -138.07% |
Based on the profitability ratios of Halozyme Therapeutics Inc over the past few quarters, there are some notable trends to consider:
1. Operating return on assets (Operating ROA) has shown fluctuation over the quarters but generally improved from negative values in early 2020 to positive levels above 20% by the end of 2024, signaling better operational efficiency and profitability.
2. Return on assets (ROA) also displayed a similar pattern of improvement, starting from negative percentages to reaching levels above 20% by the end of 2024, indicating that the company is effectively utilizing its assets to generate profits.
3. Return on total capital exhibited substantial growth throughout the quarters, showcasing a significant increase in the efficient use of total capital to generate returns, with the ratio soaring to over 400% by the end of 2023 before moderating slightly in 2024.
4. Return on equity (ROE) demonstrated remarkable growth over the quarters, indicating that the company's shareholders' equity is being effectively utilized to generate profits. The ratio increased from negative levels to surpassing 300% by mid-2023 and continued to show strong performance into 2024, albeit with a slight decrease in the rate of growth.
Overall, the profitability ratios of Halozyme Therapeutics Inc reflect a positive trend in operational efficiency, asset utilization, capital management, and shareholder value creation over the analyzed period.